The global market for bovine respiratory disease treatment features a highly consolidated competitive landscape despite the presence of a large number of regional players, observes a recent report by Transparency Market Research. Owing to the small duration of product exclusivity in the animal health care industry – about three to five years – competition from generics and over-the-counter (OTC) products is a big threat.
The rising consumption of bovine products in emerging economies such as India, China, and Brazil, the demand for effective treatment methods for respiratory disease has considerably increased. To exploit the vast growth potential, an increasing number of companies are establishing operations in these countries. A recent example is the 2016 collaboration between Merial and Zoetis, Inc., which is expected to allow the former to effectively market and distribute its product in India. Some of the other key companies in the market are Merck & Co., Inc., Bayer AG, Elanco, Boehringer Ingelheim GmbH, and Virbac Group.